• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[REGICOR研究人群队列中10年心血管疾病风险评估的相对有效性]

[Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study].

作者信息

Marrugat Jaume, Vila Joan, Baena-Díez José Miguel, Grau María, Sala Joan, Ramos Rafel, Subirana Isaac, Fitó Montserrat, Elosua Roberto

机构信息

Grupo de Epidemiología y Genética Cardiovascular, Instituto Municipal de Investigación Médica, Barcelona, España.

出版信息

Rev Esp Cardiol. 2011 May;64(5):385-94. doi: 10.1016/j.recesp.2010.12.011. Epub 2011 Apr 8.

DOI:10.1016/j.recesp.2010.12.011
PMID:21482004
Abstract

INTRODUCTION AND OBJECTIVES

Cardiovascular risk screening requires accurate risk functions. The relative validity of the Framingham-based REGICOR adapted function is analyzed and the population distribution of cardiovascular 10-year cardiovascular events is described by risk group.

METHODS

A population cohort of 3856 participants recruited between 1995 and 2000, aged 35 to 74 years from Girona without symptoms of cardiovascular diseases, was followed between 2006 and 2009. Standardized laboratory and blood pressure measurements, questionnaires, and case definitions were used. The follow-up combined cross-linkage of our databases with our regional mortality registry, reexamination, and telephone contact with participants. Coronary disease endpoints alone were considered.

RESULTS

A total of 27 487 person-years were obtained (mean follow-up 7.1 years), and the follow-up was achieved in 97% of participants (120 coronary disease events). Validity was good: the regression coefficients estimated with the cohort data did not differ from those obtained in the original Framingham function. Function calibration was good: the observed incidence of cardiovascular events in the decile groups of risk did not differ from the function prediction (P=.127 in women, and P=.054 in men). The C statistic (discrimination) was 0.82 (95% confidence interval, 0.76-0.88) in women, and 0.78 (95% confidence interval, 0.73-0.83) in men. More than 50% of cardiovascular events occurred in participants whose 10-year risk was 5% to 14.9%.

CONCLUSIONS

The studied function accurately predicts coronary disease events at 10 years. Risk stratification could be simplified in 4 groups: low (<5%), moderate (5%-9.9%), high (10%-14.9%) and very high (≥15%).

摘要

引言与目的

心血管风险筛查需要准确的风险函数。分析了基于弗雷明汉的REGICOR适配函数的相对有效性,并按风险组描述了心血管10年心血管事件的人群分布。

方法

对1995年至2000年间招募的3856名年龄在35至74岁之间、来自赫罗纳且无心血管疾病症状的参与者组成的人群队列,在2006年至2009年期间进行随访。使用了标准化的实验室和血压测量、问卷以及病例定义。随访结合了我们数据库与区域死亡率登记处的交叉链接、重新检查以及与参与者的电话联系。仅考虑冠心病终点。

结果

共获得27487人年(平均随访7.1年),97%的参与者完成了随访(120例冠心病事件)。有效性良好:用队列数据估计的回归系数与原始弗雷明汉函数获得的系数无差异。函数校准良好:风险十分位数组中心血管事件的观察发病率与函数预测无差异(女性P = 0.127,男性P = 0.054)。女性的C统计量(区分度)为0.82(95%置信区间,0.76 - 0.88),男性为0.78(95%置信区间,0.73 - 0.83)。超过50%的心血管事件发生在10年风险为5%至14.9%的参与者中。

结论

所研究的函数能准确预测10年冠心病事件。风险分层可简化为4组:低(<5%)、中(5% - 9.9%)、高(10% - 14.9%)和非常高(≥15%)。

相似文献

1
[Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study].[REGICOR研究人群队列中10年心血管疾病风险评估的相对有效性]
Rev Esp Cardiol. 2011 May;64(5):385-94. doi: 10.1016/j.recesp.2010.12.011. Epub 2011 Apr 8.
2
Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: the FRESCO Study.西班牙一组10年心血管疾病风险预测函数的推导与验证:FRESCO研究
Prev Med. 2014 Apr;61:66-74. doi: 10.1016/j.ypmed.2013.12.031. Epub 2014 Jan 9.
3
Performance of Framingham cardiovascular risk scores by ethnic groups in New Zealand: PREDICT CVD-10.新西兰不同种族的弗雷明汉心血管风险评分表现:PREDICT CVD - 10。
N Z Med J. 2010 Feb 19;123(1309):50-61.
4
[Estimating cardiovascular risk in Spain using different algorithms].[使用不同算法评估西班牙的心血管风险]
Rev Esp Cardiol. 2007 Jul;60(7):693-702.
5
Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study.弗雷明汉心血管风险函数改编版的有效性:VERIFICA研究。
J Epidemiol Community Health. 2007 Jan;61(1):40-7. doi: 10.1136/jech.2005.038505.
6
The risk functions incorporated in Riscard 2002: a software for the prediction of cardiovascular risk in the general population based on Italian data.Riscard 2002中纳入的风险函数:一款基于意大利数据预测普通人群心血管风险的软件。
Ital Heart J. 2002 Feb;3(2):114-21.
7
Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function.荷兰首发冠心病风险预测:SCORE 风险函数的再估计和改进。
Eur J Prev Cardiol. 2012 Aug;19(4):840-8. doi: 10.1177/1741826711410256. Epub 2011 May 6.
8
Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level.弗明汉心脏研究风险方程可预测新西兰人群层面首次心血管事件的发生率。
N Z Med J. 2003 Nov 7;116(1185):U662.
9
Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.长期暴露于交通相关空气污染对荷兰呼吸道和心血管疾病死亡率的影响:荷兰长期队列空气污染研究(NLCS-AIR研究)
Res Rep Health Eff Inst. 2009 Mar(139):5-71; discussion 73-89.
10
Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.预测5年内心血管疾病和中风的人群水平风险降低对急性住院率的影响——一项试点研究。
Public Health. 2006 Dec;120(12):1140-8. doi: 10.1016/j.puhe.2006.10.012. Epub 2006 Nov 3.

引用本文的文献

1
Saudi Heart Association Position Statement on Troponin use for Cardiovascular Risk Screening in Asymptomatic Populations.沙特心脏协会关于肌钙蛋白用于无症状人群心血管风险筛查的立场声明。
J Saudi Heart Assoc. 2025 Jul 16;37(3):10. doi: 10.37616/2212-5043.1444. eCollection 2025.
2
Persistent inflammatory activation in people living with HIV. Involvement in atherosclerosis.艾滋病毒感染者体内持续的炎症激活。与动脉粥样硬化的关系。
Front Med (Lausanne). 2025 Jul 11;12:1621765. doi: 10.3389/fmed.2025.1621765. eCollection 2025.
3
Cohort Profile: The Girona Heart Registry.
队列简介:赫罗纳心脏注册研究
Int J Epidemiol. 2025 Jun 11;54(4). doi: 10.1093/ije/dyaf116.
4
Health program for prEvention of cardiovascuLar disEases based on a risk screeNing strategy with Ankle-brachial index: HELENA study protocol.基于踝臂指数风险筛查策略的心血管疾病预防健康项目:海伦娜研究方案
Front Public Health. 2025 May 30;13:1484163. doi: 10.3389/fpubh.2025.1484163. eCollection 2025.
5
Cohort profile: the CORDELIA study (Collaborative cOhorts Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses).队列简介:CORDELIA研究(协作队列重组数据以研究慢性疾病的机制和长期发病率)
Eur J Epidemiol. 2025 May 12. doi: 10.1007/s10654-025-01229-6.
6
Major Limitations of Cardiovascular Risk Scores.心血管风险评分的主要局限性。
Cardiovasc Ther. 2024 Feb 28;2024:4133365. doi: 10.1155/2024/4133365. eCollection 2024.
7
Prevalence of Cardiovascular Risk Factors in Spain: A Systematic Review.西班牙心血管危险因素的患病率:一项系统综述。
J Clin Med. 2023 Nov 6;12(21):6944. doi: 10.3390/jcm12216944.
8
[Luces y sombras de la Guía Europea esc-2021 de Prevención de la Enfermedad Cardiovascular en la Práctica Clínica.].[《欧洲临床实践中预防心血管疾病指南(esc - 2021)的利弊》]
Rev Esp Salud Publica. 2023 Aug 16;97:e202308064.
9
Using Mathematical and Statistical Analysis to Investigate the Correlation between Exacerbation of Chronic Obstructive Pulmonary Disease and Risk of Subclinical Atherosclerosis.运用数学和统计分析研究慢性阻塞性肺疾病急性加重与亚临床动脉粥样硬化风险之间的相关性。
Diagnostics (Basel). 2023 Feb 8;13(4):623. doi: 10.3390/diagnostics13040623.
10
High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention.高敏肌钙蛋白:一级预防中潜在的心血管风险生物标志物。
Front Cardiovasc Med. 2022 Nov 30;9:1054959. doi: 10.3389/fcvm.2022.1054959. eCollection 2022.